

Kyowa Hakko Kirin Co., Ltd.

Appendix to the Fiscal 2013 First Quarter Consolidated Financial Statements

First quarter results for Fiscal 2013
(January 1, 2013 - March 31, 2013)

Index	Page
I. Consolidated Financial Results	
1. Trends in consolidated income	1
2. Trends in results by segment	2
3. Other trends	3
II. Consolidated Subsidiaries and Affiliates	4
III. Kyowa Hakko Kirin Sales of main products	
Accumulative	5
Quarterly	6
IV. Segment information and main subsidiaries operating profit or loss	
1. Pharmaceuticals segment	7
2. Bio-Chemicalss segment	8
R&D Pipeline	9, 10

- This document was made as a supplement to the Kessan Tanshin (financial report) for the first quarter of Fiscal 2013, the three-month period from January 1, 2013 to March 31, 2013.
- This document contains forward-looking statements based on a number of assumptions and beliefs made by management in light of information currently available. For a variety of reasons, actual financial results may differ materially from the forecasts presented here.
- Figures presented in this document have been rounded down to the nearest whole number.
- The average exchange rate for each period was as follows.

Unit: yen

	2012 results				2013 results				2013 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Jun	Jan - Dec
US \$	79	80	79	80	89	-	-	-	85	85
Euro	104	103	102	103	118	-	-	-	115	115
GBP	125	126	125	127	141	-	-	-	140	140

Contact
 Kyowa Hakko Kirin Co., Ltd.
 Corporate Communications Department
 Tel 81 3 3282 0009

I. Consolidated Financial Results

1. Trends in consolidated income Accumulative

Billions of yen, rounded down

	FY 2012 results				FY 2013 results								FY 2013 forecasts				
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change Amount	Change %	Jan - Jun	Change %	Jan - Sep	Change %	Jan - Dec	Change %	Jan - Jun	Change %	Jan - Dec	Change %
Net sales	87.1	166.2	244.6	333.1	86.6	(0.4)	99%	-	-	-	-	-	-	169.0	102%	338.0	101%
Gross Profit	55.0	104.3	154.3	210.6	52.3	(2.6)	95%	-	-	-	-	-	-	-	-	-	-
Selling, general and administrative expenses	36.9	78.7	117.0	157.7	37.8	0.9	102%	-	-	-	-	-	-	-	-	-	-
Operating income (prior to amortization of goodwill)	20.3	30.2	44.2	62.1	16.7	(3.5)	82%	-	-	-	-	-	-	33.6	111%	64.2	103%
Operating income	18.0	25.5	37.3	52.9	14.4	(3.5)	80%	-	-	-	-	-	-	29.0	113%	55.0	104%
Other income	1.6	1.4	1.9	4.1	1.0	(0.6)	63%	-	-	-	-	-	-	-	-	-	-
Other expenses	3.1	3.9	6.6	8.0	0.6	(2.4)	22%	-	-	-	-	-	-	-	-	-	-
Ordinary income	16.5	23.0	32.5	49.0	14.8	(1.7)	90%	-	-	-	-	-	-	-	-	49.0	100%
Extraordinary income	-	-	-	-	3.8	3.8	-	-	-	-	-	-	-	-	-	-	-
Extraordinary expenses	0.3	0.3	1.2	3.9	-	(0.30)	-	-	-	-	-	-	-	-	-	-	-
Net income before income taxes	16.2	22.7	31.3	45.0	18.6	2.4	115%	-	-	-	-	-	-	-	-	52.0	115%
Corporate, local and enterprise taxes	7.7	11.2	15.8	20.6	8.1	0.4	106%	-	-	-	-	-	-	-	-	-	-
Income from minority interests	0.0	0.0	0.0	0.2	0.0	(0.0)	52%	-	-	-	-	-	-	-	-	-	-
Net income	8.5	11.5	15.4	24.1	10.4	1.9	123%	-	-	-	-	-	-	-	-	30.0	124%
Comprehensive income	15.0	13.3	18.3	34.7	16.8	1.7	112%	-	-	-	-	-	-	-	-	-	-
EPS prior to amortization of goodwill (¥/share)	19.66	29.40	40.79	61.00	23.39	3.73	119%	-	-	-	-	-	-	-	-	71.71	118%

*1 "Prior to amortization of goodwill" refers to profits prior to the deduction of amortization of the goodwill *arising on the reverse acquisition in April 2008 (Kirin Pharma share transfer).
(Note: This adjustment does not include goodwill amortization in respect of the acquisition of ProStrakan.)

*2 There are no changes to the consolidated results forecasts for the fiscal year ending December 31, 2013 announced on January 31, 2013.

Quarterly

Billions of yen, rounded down

	FY 2012 results				FY 2013 results								FY 2013 forecasts				
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Change Amount	Change %	Apr - Jun	Change %	Jul - Sep	Change %	Oct - Dec	Change %	Jan - Jun	Change %	Jul - Dec	Change %
Net sales	87.1	79.1	78.4	88.4	86.6	(0.4)	99%	-	-	-	-	-	-	169.0	102%	169.0	101%
Gross Profit	55.0	49.3	50.0	56.3	52.3	(2.6)	95%	-	-	-	-	-	-	-	-	-	-
Selling, general and administrative expenses	36.9	41.7	38.3	40.7	37.8	0.9	102%	-	-	-	-	-	-	-	-	-	-
Operating income (Prior to amortization of goodwill)	20.3	9.8	14.0	17.8	16.7	(3.5)	82%	-	-	-	-	-	-	33.6	111%	30.6	96%
Operating income	18.0	7.5	11.7	15.5	14.4	(3.5)	80%	-	-	-	-	-	-	29.0	113%	26.0	95%
Other income	1.6	(0.2)	0.5	2.2	0.1	(0.6)	63%	-	-	-	-	-	-	-	-	-	-
Other expenses	3.1	0.7	2.7	1.3	0.6	(2.4)	22%	-	-	-	-	-	-	-	-	-	-
Ordinary income	16.5	6.5	9.4	16.4	14.8	(1.7)	90%	-	-	-	-	-	-	-	-	-	-
Extraordinary income	-	-	-	-	3.8	3.8	-	-	-	-	-	-	-	-	-	-	-
Extraordinary expenses	0.3	-	0.9	2.7	-	(0.3)	-	-	-	-	-	-	-	-	-	-	-
Net income before income taxes	16.2	6.5	8.5	13.6	18.6	2.4	115%	-	-	-	-	-	-	-	-	-	-
Corporate, local and enterprise taxes	7.7	3.4	4.6	4.7	8.1	0.4	106%	-	-	-	-	-	-	-	-	-	-
Income from minority interests	0.0	0.0	0.0	0.1	0.0	(0.0)	52%	-	-	-	-	-	-	-	-	-	-
Net income	8.5	3.0	3.9	8.7	10.4	1.9	123%	-	-	-	-	-	-	-	-	-	-
EPS prior to amortization of goodwill (¥/share)	19.66	9.72	11.38	20.23	23.39	3.73	119%	-	-	-	-	-	-	-	-	-	-

I. Consolidated Financial Results

2. Trends in results by segment

Accumulative

Billions of yen, rounded down

	FY 2012 results				FY 2013 results								FY 2013 forecasts				
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change Amount	Change %	Jan - Jun	Change %	Jan - Sep	Change %	Jan - Dec	Change %	Jan - Jun	Change %	Jan - Dec	Change %
Net sales	87.1	166.2	244.6	333.1	86.6	(0.4)	99%	-	-	-	-	-	-	169.0	102%	338.0	101%
Pharmaceuticals	67.2	127.5	189.4	259.3	67.4	0.2	100%	-	-	-	-	-	-	130.0	102%	260.0	100%
Bio-Chemicals	20.5	40.0	57.4	76.9	19.9	(0.5)	97%	-	-	-	-	-	-	40.0	100%	81.0	105%
Total	87.8	167.6	246.9	336.3	87.4	(0.3)	100%	-	-	-	-	-	-	170.0	101%	341.0	101%
Eliminations	(0.6)	(1.3)	(2.2)	(3.1)	(0.7)	(0.0)	-	-	-	-	-	-	-	(1.0)	-	(3.0)	-
Operating income	18.0	25.5	37.3	52.9	14.4	(3.5)	80%	-	-	-	-	-	-	29.0	113%	55.0	104%
*Before goodwill amortization	20.3	30.2	44.2	62.1	17.2	(3.1)	85%	-	-	-	-	-	-	33.6	111%	64.2	103%
Pharmaceuticals	16.7	23.5	35.1	50.7	13.0	(3.6)	78%	-	-	-	-	-	-	25.6	109%	49.2	97%
18.8	27.8	41.5	59.3	15.2	(3.6)	81%	-	-	-	-	-	-	29.9	107%	57.8	97%	
Bio-Chemicals	1.3	2.0	2.2	2.1	1.4	0.1	114%	-	-	-	-	-	-	3.4	167%	5.8	273%
1.4	2.3	2.6	2.7	2.1	0.6	144%	-	-	-	-	-	-	3.7	158%	6.4	233%	
Total	18.0	25.5	37.3	52.8	14.5	(3.4)	81%	-	-	-	-	-	-	29.0	113%	55.0	104%
20.3	30.1	44.2	62.1	17.3	(3.0)	85%	-	-	-	-	-	-	33.6	111%	64.2	103%	
Eliminations	0.0	0.0	0.0	0.0	(0.0)	(0.0)	-	-	-	-	-	-	-	-	-	-	-

*The Other segment has been discontinued from 2013. As a result figures for 2012 results and 2013 forecasts have been restated in accordance with the 2013 revised segmental classification.

Quarterly

Billions of yen, rounded down

	FY 2012 results				FY 2013 results								FY 2013 forecasts				
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Change Amount	Change %	Apr - Jun	Change %	Jul - Sep	Change %	Oct - Dec	Change %	Jan - Jun	Change %	Jul - Dec	Change %
Net sales	87.1	79.1	78.4	88.4	86.6	(0.4)	99%	-	-	-	-	-	-	169.0	102%	169.0	101%
Pharmaceuticals	67.2	60.3	61.8	69.8	67.4	0.2	100%	-	-	-	-	-	-	130.0	102%	130.0	99%
Bio-Chemicals	20.5	19.4	17.4	19.4	19.9	(0.5)	97%	-	-	-	-	-	-	40.0	100%	41.0	111%
Total	87.8	79.8	79.3	89.3	87.4	(0.3)	100%	-	-	-	-	-	-	170.0	101%	171.0	101%
Eliminations	(0.6)	(0.6)	(0.9)	(0.8)	(0.7)	(0.0)	-	-	-	-	-	-	-	(1.0)	-	(2.0)	-
Operating income	18.0	7.5	11.7	15.5	14.4	(3.5)	80%	-	-	-	-	-	-	29.0	113%	26.0	95%
*Before goodwill amortization	20.3	9.8	14.0	17.8	17.2	(3.1)	85%	-	-	-	-	-	-	33.6	111%	30.6	96%
Pharmaceuticals	16.7	6.7	11.5	15.6	13.0	(3.6)	78%	-	-	-	-	-	-	25.6	109%	23.6	87%
18.8	8.9	13.7	17.7	15.2	(3.6)	81%	-	-	-	-	-	-	29.9	107%	27.9	89%	
Bio-Chemicals	1.3	0.7	0.1	0.0	1.4	0.1	114%	-	-	-	-	-	-	3.4	167%	2.4	-
1.4	0.8	0.3	0.0	0.0	2.1	0.6	144%	-	-	-	-	-	3.7	158%	2.7	678%	
Total	18.0	7.5	11.7	15.5	14.5	(3.4)	81%	-	-	-	-	-	-	29.0	113%	26.0	95%
20.3	9.8	14.0	17.8	17.3	(3.0)	85%	-	-	-	-	-	-	33.6	111%	30.6	96%	
Eliminations	0.0	0.0	0.0	0.0	(0.0)	(0.0)	-	-	-	-	-	-	-	-	-	-	-

(2) Regional sales

Billions of yen, rounded down

	FY 2012 results				FY 2013 results											
	Jan - Mar	Percentage of consolidated sales	Jan - Jun	Percentage of consolidated sales	Jan - Sep	Percentage of consolidated sales	Jan - Dec	Percentage of consolidated sales	Jan - Mar	Percentage of consolidated sales	Jan - Jun	Percentage of consolidated sales	Jan - Sep	Percentage of consolidated sales	Jan - Dec	Percentage of consolidated sales
Japan sales	68.9	79.1%	128.8	77.5%	189.9	77.6%	260.5	78.2%	66.1	76.3%	-	-	-	-	-	-
Overseas sales	18.1	20.9%	37.3	22.5%	54.7	22.4%	72.6	21.8%	20.5	23.7%	-	-	-	-	-	-
America	4.6	5.3%	10.0	6.1%	15.0	6.2%	21.2	6.4%	5.2	6.0%	-	-	-	-	-	-
Europe	8.4	9.7%	16.9	10.2%	24.0	9.8%	30.9	9.3%	9.4	10.9%	-	-	-	-	-	-
Asia	4.9	5.7%	10.0	6.1%	15.2	6.2%	19.8	6.0%	5.7	6.6%	-	-	-	-	-	-
Other regions	0.1	0.1%	0.2	0.2%	0.4	0.2%	0.5	0.2%	0.1	0.2%	-	-	-	-	-	-
Total consolidated net sales	87.1	100.0%	166.2	100.0%	244.6	100.0%	333.1	100.0%	86.6	100.0%	-	-	-	-	-	-

* Sales classified by region or country based on location of customer.

I. Consolidated Financial Results

3. Other trends

(1) R&D Expenses

Billions of yen, rounded down

	FY 2012 results				FY 2013 results				FY 2013 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Jun	Jan - Dec
R&D expenses	11.0	22.1	33.6	44.8	10.6	-	-	-	22.2	44.0
R&D to net sales ratio	12.7%	13.3%	13.8%	13.4%	12.3%	-	-	-	13.2%	13.0%
Pharmaceuticals	10.3	20.5	31.3	41.3	9.8	-	-	-	20.5	40.7
R&D to net sales ratio	15.3%	16.1%	16.5%	15.9%	14.7%	-	-	-	15.8%	15.7%
Bio-Chemicals	0.7	1.5	2.3	3.4	0.7	-	-	-	1.7	3.3

(2) Capital Expenditure (Tangible fixed assets)

Billions of yen, rounded down

	FY 2012 results				FY 2013 results				FY 2013 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Jun	Jan - Dec
Capital expenditure	4.1	7.9	14.7	19.7	5.3	-	-	-	7.4	19.2
Pharmaceuticals	2.1	4.0	7.3	10.3	1.8	-	-	-	3.7	9.5
Bio-Chemicals	1.9	3.9	7.4	9.4	3.5	-	-	-	3.7	9.7

(3) Depreciation Expenses (Tangible and intangible fixed assets)

Billions of yen, rounded down

	FY 2012 results				FY 2013 results				FY 2013 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Jun	Jan - Dec
Depreciation and amortization expenses	4.6	9.6	14.5	20.9	4.8	-	-	-	9.9	21.2
Amortization of intangible fixed assets	1.0	2.4	3.5	5.4	1.5	-	-	-	2.9	6.1
Pharmaceuticals	3.1	6.6	10.1	14.5	3.3	-	-	-	6.7	14.6
Amortization of intangible fixed assets	1.0	2.4	3.5	5.4	1.5	-	-	-	2.8	6.1
Bio-Chemicals	1.5	2.9	4.4	6.2	1.5	-	-	-	3.1	6.6

*Depreciation expenses for intangible fixed assets do not include goodwill amortization expenses

(4) Goodwill Amortization Expenses

Billions of yen, rounded down

	FY 2012 results				FY 2013 results				FY 2013 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Jun	Jan - Dec
Amortization expenses	3.0	6.0	9.1	12.0	2.8	-	-	-	5.7	11.4
Reverse acquisition goodwill amortization expenses	2.3	4.6	6.9	9.2	2.3	-	-	-	4.6	9.2
Pharmaceuticals	2.9	5.7	8.6	11.4	2.7	-	-	-	5.4	10.8
Reverse acquisition goodwill amortization	2.1	4.3	6.4	8.6	2.1	-	-	-	4.3	8.6
Bio-Chemicals	0.1	0.3	0.4	0.6	0.1	-	-	-	0.3	0.6
Reverse acquisition goodwill amortization	0.1	0.3	0.4	0.6	0.1	-	-	-	0.3	0.6

**Reverse acquisition goodwill amortization expenses* refers to amortization of goodwill arising on the reverse acquisition in April 2008 (Kirin Pharma share transfer).

II. Consolidated Subsidiaries and Affiliates

(As of March 31, 2013)

Segment	Type	Region	Company name	Percentage owned (direct and indirect)	Principal business
Pharmaceuticals	Consolidated subsidiary	Japan	Kyowa Medex Co., Ltd.	100.0%	Manufacture and sale of diagnostic reagents
			Kyowa Medical Promotion Co., Ltd.	100.0%	Promotion and sales of pharmaceuticals
			Chiyoda Kaihatsu Co., Ltd. *1	100.0%	Distribution, contracting, wholesale and retail and insurance agency business
		The Americas	Kyowa Hakko Kirin America, Inc.	100.0%	Holding company for administration and management of subsidiaries (US)
			BioWa, Inc.	100.0%	Out-licensing of anti-body technology (US)
			Kyowa Hakko Kirin Pharma, Inc.	100.0%	Development of outsourced pharmaceutical products (US)
			Kyowa Hakko Kirin California, Inc.	100.0%	Generate new candidate substances and develop pharmaceuticals (US)
			Hematech, Inc.	100.0%	(Company to be discontinued)
			ProStrakan Inc.	100.0%	Sales of pharmaceuticals (US)
			Europe	ProStrakan Group plc	100.0%
		Strakan Inernational S.a r.l.		100.0%	Sales, licensing-in and licensing-out of pharmaceuticals (UK)
		Strakan Pharmaceuticals Limited		100.0%	Development of pharmaceuticals (UK)
		ProStrakan Limited		100.0%	Sales of pharmaceuticals (UK)
		ProStrakan Pharma S.A.S		100.0%	Sales of pharmaceuticals (France)
		ProStrakan Farmaceutica SLU		100.0%	Sales of pharmaceuticals (Spain)
		ProStrakan Pharma GmbH		100.0%	Sales of pharmaceuticals (Germany)
		ProStrakan Holdings B.V.		100.0%	Holding company for special companies (Netherlands)
		ProStrakan Pharma B.V.		100.0%	Sales of pharmaceuticals (Netherlands)
		Asia	ProStrakan S.r.l.	100.0%	Sales of pharmaceuticals (Italy)
	ProStrakan AB		100.0%	Sales of pharmaceuticals (Sweden)	
	Kyowa Hakko Kirin China Pharmaceutical Co., Ltd.		100.0%	Manufacture and sale of pharmaceuticals (China)	
	Kyowa Hakko Kirin Korea Co., Ltd.		100.0%	Sales of pharmaceuticals (Korea)	
	Kyowa Hakko Kirin (Taiwan) Co., Ltd.		100.0%	Sales of pharmaceuticals (Taiwan)	
Affiliate accounted for by the equity method	Japan	FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.	50.0%	Development, manufacture and sale of biosimilar pharmaceuticals	
		Japan Synthetic Alcohol Co., Ltd. *1	33.3%	Manufacture and sale of industrial alcohol	
Bio-Chemicals	Consolidated subsidiary	Japan	Kyowa Hakko Bio Co., Ltd.	100.0%	Manufacture and sale of pharmaceutical and industrial raw materials, and health care products
			Daiichi Fine Chemical Co., Ltd.	100.0%	Manufacture and sale of active pharmaceutical ingredients and pharmaceutical intermediates
			Kyowa Engineering Co., Ltd.	100.0%	Design and installation of plant facilities and equipment
		The Americas	BioKyowa Inc.	100.0%	Manufacture and sale of amino acids (US)
			Kyowa Hakko U.S.A., Inc.	100.0%	Sale and import/export of fine chemicals including amino acids (US)
			Kyowa Hakko Bio U.S. Holdings, Inc.	100.0%	Holding company for administration and management of US special companies (US)
		Europe	Kyowa Hakko Europe GmbH	100.0%	Sale and import/export of fine chemicals including amino acids (Germany)
			Kyowa Hakko Bio Italia S.r.l.	100.0%	Sale and import/export of fine chemicals including amino acids (Italy)
		Asia	Shanghai Kyowa Amino Acid Co., Ltd.	70.0%	Manufacture and sale of amino acids (China)
			Thai Kyowa Biotechnologies Co., Ltd.	100.0%	Manufacture and sale of amino acids (Thailand)
			Kyowa Hakko (H.K.) Co., Ltd.	100.0%	Sale and import/export of fine chemicals including amino acids (Hong Kong)
			Kyowa Hakko Bio Singapore Pte. Ltd.	100.0%	Sale and import/export of fine chemicals including amino acids (Singapore)

Changes in scope of consolidation resulting in changes in subsidiaries (2013.1.1~2013.3.31)

New: None

Exclusions: One: Kyowa Hakko Wellness (see Note 2)

Notes: 1. As a result of the discontinuation of the "Other" segment from 2013 Chiyoda Kaihatsu Co., and Japan Synthetic Alcohol Co., Ltd. have been included in the Pharmaceuticals segment.

2. Kyowa Hakko Wellness no longer exists following its merger with Kyowa Hakko Bio on January 1, 2013.

III. Kyowa Hako Kirin Sales of main products

Accumulative

Billions of yen, rounded down

	FY 2012 results				FY 2013 results								FY 2013 forecasts				
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change Amount	Change %	Jan - Jun	Change %	Jan - Sep	Change %	Jan - Dec	Change %	Jan - Jun	Change %	Jan - Dec	Change %
Kyowa Hako Kirin total	57.8	107.8	159.4	218.1	56.4	(1.4)	98%	-	-	-	-	-	-	108.7	101%	212.3	97%
Indication / Product name																	
<i>ESA formulation</i> Nesp	13.8	26.8	41.0	58.1	10.6	(3.1)	77%	-	-	-	-	-	-	27.7	103%	57.8	99%
<i>ESA formulation</i> Espo	0.9	1.9	2.9	3.9	0.7	(0.2)	71%	-	-	-	-	-	-	1.7	90%	3.5	90%
Nesp/Espo	14.8	28.8	43.9	62.0	11.3	(3.4)	77%	-	-	-	-	-	-	29.5	102%	61.3	99%
<i>Secondary hyperparathyroidism</i> Regpara	2.8	6.2	9.5	13.4	3.0	0.2	110%	-	-	-	-	-	-	6.7	109%	14.1	105%
<i>Secondary hyperparathyroidism</i> Rocatriol	0.7	1.6	2.5	3.6	0.7	0.0	104%	-	-	-	-	-	-	1.8	108%	3.6	101%
<i>Antiallergenic</i> Allelock	9.9	16.1	21.8	29.9	10.7	0.8	109%	-	-	-	-	-	-	16.2	100%	27.8	93%
<i>Antiallergenic</i> Celect	0.5	1.0	1.4	1.9	0.4	(0.0)	89%	-	-	-	-	-	-	1.0	97%	1.8	96%
<i>Antiallergic eyedrops</i> Patanol	5.4	6.9	8.5	10.2	9.4	3.9	172%	-	-	-	-	-	-	8.1	117%	11.4	111%
<i>G-CSF</i> Gran	2.9	6.4	9.8	13.5	2.5	(0.3)	87%	-	-	-	-	-	-	6.0	94%	12.6	93%
<i>Cancer pain</i> Fentos	0.8	2.0	3.2	4.6	1.0	0.1	118%	-	-	-	-	-	-	2.4	120%	5.5	119%
<i>Anticancer</i> 5-FU	0.6	1.4	2.1	2.8	0.6	(0.0)	90%	-	-	-	-	-	-	1.4	100%	2.8	99%
<i>Anticancer</i> Navelbine	0.3	0.6	0.9	1.3	0.2	(0.0)	79%	-	-	-	-	-	-	0.6	90%	1.1	88%
<i>Chronic idiopathic thrombocytopenic purpura</i> Romiplate	0.3	0.7	1.2	1.7	0.4	0.1	138%	-	-	-	-	-	-	0.8	116%	1.8	102%
<i>Cardiovascular</i> Coniel	4.2	8.5	12.5	17.1	3.5	(0.6)	84%	-	-	-	-	-	-	7.6	90%	15.4	90%
<i>Cardiovascular (Hypertension)</i> Coversyl	0.8	1.7	2.5	3.5	0.7	(0.0)	95%	-	-	-	-	-	-	1.5	89%	3.1	88%
<i>Cardiovascular</i> Inovan / Pre Dopa *1	0.6	1.1	1.7	2.4	0.4	(0.1)	76%	-	-	-	-	-	-	0.9	80%	1.8	79%
<i>Antiepileptic</i> Depakene	2.4	5.2	7.8	10.7	2.3	(0.1)	95%	-	-	-	-	-	-	5.1	99%	10.5	99%
<i>Parkinson's disease</i> Permax	0.3	0.8	1.2	1.7	0.3	(0.0)	76%	-	-	-	-	-	-	0.8	100%	1.7	103%
<i>Gastrointestinal</i> Nauzelin	1.1	2.2	3.2	4.9	1.0	(0.0)	95%	-	-	-	-	-	-	2.4	107%	4.9	100%
<i>Inflammatory bowel disease</i> Asacol	0.8	1.8	2.8	4.1	1.0	0.2	135%	-	-	-	-	-	-	2.3	127%	4.8	117%
Exports and Technology Out-Licensing																	
Exports	3.1	5.7	7.5	9.4	3.2	0.0	103%	-	-	-	-	-	-	4.6	82%	9.2	98%
Technology Out-Licensing	8.1	12.0	18.9	24.4	4.8	(3.2)	60%	-	-	-	-	-	-	11.3	95%	18.8	77%

*1 Sales of Pre Dopa terminated on February 28, 2013. As a result Inovan/ Pre Dopa from March 2013 are figure for Inovan only.

III. Kyowa Hako Kirin Sales of main products

Quarterly

Billions of yen, rounded down

	FY 2012 results				FY 2013 results								FY 2013 forecasts				
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Change Amount	Change %	Apr - Jun	Change %	Jul - Sep	Change %	Oct - Dec	Change %	Jan - Jun	Change %	Jul - Dec	Change %
Kyowa Hako Kirin total	57.8	49.9	51.6	58.6	56.4	(1.4)	98%	-	-	-	-	-	-	108.7	101%	103.5	94%
Indication / Product name																	
ESA formulation Nesp	13.8	12.9	14.2	17.0	10.6	(3.1)	77%	-	-	-	-	-	-	27.7	103%	30.0	96%
ESA formulation Espo	0.9	0.9	0.9	0.9	0.7	(0.2)	71%	-	-	-	-	-	-	1.7	90%	1.7	89%
Nesp/Espo	14.8	13.9	15.1	18.0	11.3	(3.4)	77%	-	-	-	-	-	-	29.5	102%	31.8	96%
Secondary hyperparathyroidism Regpara	2.8	3.4	3.3	3.8	3.0	0.2	110%	-	-	-	-	-	-	6.7	109%	7.3	102%
Secondary hyperparathyroidism Rocartrol	0.7	0.9	0.9	1.0	0.7	0.0	104%	-	-	-	-	-	-	1.8	108%	1.8	94%
Antiallergenic Allelock	9.9	6.2	5.7	8.0	10.7	0.8	109%	-	-	-	-	-	-	16.2	100%	11.5	84%
Antiallergenic Cellect	0.5	0.4	0.3	0.4	0.4	(0.0)	89%	-	-	-	-	-	-	1.0	97%	0.8	95%
Antiallergic eyedrops Patanol	5.4	1.4	1.6	1.7	9.4	3.9	172%	-	-	-	-	-	-	8.1	117%	3.3	100%
G-CSF Gran	2.9	3.4	3.4	3.7	2.5	(0.3)	87%	-	-	-	-	-	-	6.0	94%	6.5	92%
Cancer pain Fentos	0.8	1.1	1.1	1.4	1.0	0.1	118%	-	-	-	-	-	-	2.4	120%	3.0	118%
Anticancer 5-FU	0.6	0.7	0.6	0.7	0.6	(0.0)	90%	-	-	-	-	-	-	1.4	100%	1.4	98%
Anticancer Navelbine	0.3	0.3	0.3	0.3	0.2	(0.0)	79%	-	-	-	-	-	-	0.6	90%	0.5	86%
Chronic idiopathic thrombocytopenic purpura Romiplate	0.3	0.4	0.4	0.5	0.4	0.1	138%	-	-	-	-	-	-	0.8	116%	0.9	92%
Cardiovascular Coniel	4.2	4.3	4.0	4.5	3.5	(0.6)	84%	-	-	-	-	-	-	7.6	90%	7.7	91%
Cardiovascular (Hypertension) Coversyl	0.8	0.9	0.8	0.9	0.7	(0.0)	95%	-	-	-	-	-	-	1.5	89%	1.5	87%
Cardiovascular Inovan / Pre Dopa *1	0.6	0.5	0.5	0.6	0.4	(0.1)	76%	-	-	-	-	-	-	0.9	80%	0.9	77%
Antiepileptic Depakene	2.4	2.7	2.5	2.9	2.3	(0.1)	95%	-	-	-	-	-	-	5.1	99%	5.4	98%
Parkinson's disease Permax	0.3	0.4	0.4	0.4	0.3	(0.0)	76%	-	-	-	-	-	-	0.8	100%	0.8	106%
Gastrointestinal Nauzelin	1.1	1.1	0.9	1.7	1.0	(0.0)	95%	-	-	-	-	-	-	2.4	107%	2.5	94%
Inflammatory bowel disease Asacol	0.8	1.0	1.0	1.2	1.0	0.2	135%	-	-	-	-	-	-	2.3	127%	2.4	109%
Exports and Technology Out-Licensing																	
Exports	3.1	2.5	1.8	1.8	3.2	0.0	103%	-	-	-	-	-	-	4.6	82%	4.5	123%
Technology Out-Licensing	8.1	3.8	6.9	5.5	4.8	(3.2)	60%	-	-	-	-	-	-	11.3	95%	7.4	60%

*1 Sales of Pre Dopa terminated on February 28, 2013. As a result Inovon/ Pre Dopa from March 2013 are figure for Inovon only.

IV. Segment information and main subsidiaries operating profit or loss

1. Pharmaceuticals segment

(1) Pharmaceuticals segment total

Billions of yen, rounded down

	FY 2012 results				FY 2013 results								FY 2013 forecasts				
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change Amount	Change %	Jan - Jun	Change %	Jan - Sep	Change %	Jan - Dec	Change %	Jan - Jun	Change %	Jan - Dec	Change %
Net sales	67.2	127.5	189.4	259.3	67.4	0.2	100%	-	-	-	-	-	-	130.0	102%	260.0	100%
Japan sales	56.9	105.6	157.2	215.9	55.2	(1.6)	97%	-	-	-	-	-	-	109.0	103%	215.0	100%
Overseas sales	10.3	21.9	32.2	43.3	12.1	1.8	118%	-	-	-	-	-	-	21.0	96%	45.0	104%
America	2.6	6.4	9.8	14.2	3.3	0.6	126%	-	-	-	-	-	-	6.0	93%	14.0	98%
Europe	5.2	10.3	14.6	18.9	5.8	0.5	111%	-	-	-	-	-	-	10.0	97%	21.0	111%
Asia and others	2.4	5.1	7.7	10.1	2.9	0.5	122%	-	-	-	-	-	-	5.0	98%	10.0	98%
Operating income	16.7	23.5	35.1	50.7	13.0	(3.6)	78%	-	-	-	-	-	-	25.6	109%	49.2	97%

(2) ProStrakan (GBP)

Millions of GBP, rounded down

	FY 2012 results				FY 2013 results								FY 2013 forecasts				
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change Amount	Change %	Jan - Jun	Change %	Jan - Sep	Change %	Jan - Dec	Change %	Jan - Jun	Change %	Jan - Dec	Change %
Net sales	29.3	61.4	92.6	129.4	35.7	6.4	122%	-	-	-	-	-	-	74.0	121%	154.3	119%
<i>Chemotherapy-induced nausea and vomiting drug</i>																	
Sancuso	2.8	5.9	9.5	12.3	3.0	0.1	107%	-	-	-	-	-	-	9.0	150%	19.8	161%
<i>Management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain.</i>																	
Abstral	7.2	16.3	24.5	33.9	10.5	3.2	144%	-	-	-	-	-	-	20.5	126%	42.5	125%
<i>Replacement therapy with testosterone for male hypogonadism</i>																	
Tostran	1.6	2.9	4.3	7.5	1.8	0.2	113%	-	-	-	-	-	-	5.0	175%	11.0	147%
<i>Relief of pain associated with chronic anal fissures</i>																	
Rectogesic	2.4	4.8	7.2	10.1	2.9	0.5	121%	-	-	-	-	-	-	6.1	128%	12.9	128%
<i>Osteoporosis drug</i>																	
Adcal-D3	5.9	12.5	19.0	26.3	6.7	0.7	113%	-	-	-	-	-	-	12.2	98%	26.7	101%
Others	6.0	12.0	18.1	25.8	7.0	1.0	117%	-	-	-	-	-	-	13.9	115%	27.1	105%
Product net sales (subtotal)	26.3	54.7	82.8	116.2	32.2	5.9	123%	-	-	-	-	-	-	67.0	122%	140.3	121%
Technology Out-Licensing and others	2.9	6.6	9.8	13.1	3.4	0.4	116%	-	-	-	-	-	-	7.2	109%	14.3	109%
Gross profit	19.5	40.9	64.4	91.9	27.4	7.9	140%	-	-	-	-	-	-	56.9	139%	118.1	129%
Selling, general and administrative expenses *1	18.5	38.2	55.6	72.4	19.3	0.8	105%	-	-	-	-	-	-	43.2	113%	82.3	114%
EBIDTA *2	1.0	2.6	8.7	19.5	8.0	7.0	785%	-	-	-	-	-	-	13.6	519%	35.8	184%
Goodwill amortization *1	9.8	19.1	29.4	39.4	9.9	0.1	101%	-	-	-	-	-	-	19.9	104%	39.9	101%
Operating income	(8.8)	(16.5)	(20.7)	(19.9)	(1.8)	6.9	-	-	-	-	-	-	-	(6.3)	38%	(4.1)	21%

*1 Amortization of goodwill is not included in Selling, general and administrative expenses.

Goodwill amortization= Depreciation + Goodwill amortization

*2 EBITDA= Operating income + depreciation + goodwill amortization.

*3 Geographical breakdown of sales is as follows:

UK	Europe (excluding UK)	USA	Other
31.4%	43.6%	22.9%	2.2%

(3) Kyowa Medex

Billions of yen, rounded down

	FY 2012 results				FY 2013 results								FY 2013 forecasts				
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change Amount	Change %	Jan - Jun	Change %	Jan - Sep	Change %	Jan - Dec	Change %	Jan - Jun	Change %	Jan - Dec	Change %
Net sales	2.7	5.8	8.8	11.9	2.5	(0.2)	92%	-	-	-	-	-	-	5.7	99%	12.0	101%
Japan sales	2.0	4.6	7.1	9.7	2.0	(0.0)	99%	-	-	-	-	-	-	4.7	101%	10.0	103%
Biochemical Diagnostic Reagent	0.8	1.8	2.9	4.0	0.8	(0.0)	99%	-	-	-	-	-	-	1.9	104%	4.1	104%
Immunological Diagnostic Reagent	1.0	2.2	3.4	4.7	1.0	0.0	101%	-	-	-	-	-	-	2.2	99%	4.7	100%
Other	0.2	0.5	0.7	0.9	0.2	(0.0)	95%	-	-	-	-	-	-	0.5	103%	1.1	117%
Exports	0.6	1.1	1.6	2.2	0.4	(0.1)	71%	-	-	-	-	-	-	1.0	90%	2.0	92%
Operating income	0.2	0.5	0.8	1.2	0.0	(0.2)	20%	-	-	-	-	-	-	0.4	72%	1.0	85%

IV. Segment information and main subsidiaries operating profit or loss

2. Bio-Chemicals segment

(1) Bio-Chemicals segment total

Billions of yen, rounded down

	FY 2012 results				FY 2013 results								FY 2013 forecasts				
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change Amount	Change %	Jan - Jun	Change %	Jan - Sep	Change %	Jan - Dec	Change %	Jan - Jun	Change %	Jan - Dec	Change %
Net sales	20.5	40.0	57.4	76.9	19.9	(0.5)	97%	-	-	-	-	-	-	40.0	100%	81.0	105%
Japan sales	12.7	24.5	35.0	47.7	11.5	(1.1)	91%	-	-	-	-	-	-	22.9	93%	47.3	99%
Overseas sales	7.8	15.4	22.4	29.2	8.4	0.5	107%	-	-	-	-	-	-	17.1	110%	33.7	115%
America	1.9	3.6	5.2	6.9	1.8	(0.1)	95%	-	-	-	-	-	-	4.0	110%	8.1	116%
Europe	3.2	6.5	9.3	12.0	3.6	0.4	113%	-	-	-	-	-	-	7.4	112%	14.1	117%
Asia and others	2.7	5.2	7.8	10.2	2.9	0.2	109%	-	-	-	-	-	-	5.7	109%	11.5	112%
Operating income	1.3	2.0	2.2	2.1	1.4	0.1	114%	-	-	-	-	-	-	3.4	167%	5.8	273%

(2) Kyowa Hakko Bio Co., Ltd.

Billions of yen, rounded down

	FY 2012 results				FY 2013 results								FY 2013 forecasts				
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change Amount	Change %	Jan - Jun	Change %	Jan - Sep	Change %	Jan - Dec	Change %	Jan - Jun	Change %	Jan - Dec	Change %
Net sales	12.9	25.9	38.0	51.2	13.8	0.9	107%	-	-	-	-	-	-	28.7	111%	57.2	112%
Japan sales	8.1	16.4	24.2	32.7	8.8	0.6	108%	-	-	-	-	-	-	17.9	109%	36.1	110%
Pharmaceutical and industrial materials	3.4	7.0	10.7	14.1	3.8	0.3	109%	-	-	-	-	-	-	6.8	96%	13.6	96%
Healthcare	2.2	4.7	7.1	9.3	2.4	0.1	108%	-	-	-	-	-	-	6.4	137%	13.1	140%
Other	2.3	4.6	6.4	9.2	2.5	0.1	106%	-	-	-	-	-	-	4.6	100%	9.4	102%
Exports	4.7	9.4	13.7	18.5	4.9	0.2	105%	-	-	-	-	-	-	10.7	113%	21.0	114%
Operating income	0.5	1.2	1.4	1.1	1.2	0.7	227%	-	-	-	-	-	-	1.8	151%	3.6	316%

(3) Daiichi Fine Chemical Co., Ltd.

Billions of yen, rounded down

	FY 2012 results				FY 2013 results								FY 2013 forecasts				
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change Amount	Change %	Jan - Jun	Change %	Jan - Sep	Change %	Jan - Dec	Change %	Jan - Jun	Change %	Jan - Dec	Change %
Net sales	3.7	6.7	8.8	12.8	2.9	(0.8)	77%	-	-	-	-	-	-	5.8	86%	12.5	98%
Operating income	0.2	(0.2)	(0.6)	(1.0)	(0.0)	(0.2)	-	-	-	-	-	-	-	(0.1)	-	(0.3)	-







R&D Pipeline

KYOWA KIRIN















antibody protein small molecule

Filed • Approved

As of April 17th 2013











Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		KW-2246 Fentanyl citrate Sublingual Tablet	μ -Opioid Receptor Agonist	Cancer Pain	Filed in JP	Licensed from Orexo	
		Granisetron Patch	5HT ₃ Serotonin Receptor Antagonist	Chemotherapy induced Nausea and Vomiting	Approved in HK March 2013 Filed in Asia	Licensed from Solasia Pharma (ProStrakan)	Asia: Singapore and Malaysia
Nephrology		Cinacalcet Hydrochloride Oral	Calcium Receptor Agonist	Secondary Hyperparathyroidism	Filed in Asia	Licensed from NPS	Asia: Philippine, Malaysia, Thailand and China
		KRN321 Darbepoetin Alfa Injection	Long-Acting Erythropoiesis Stimulating Agent	Pediatric Renal Anemia	Filed in JP	Kirin- Amgen	
Central Nervous System		©KW-6002 Istradefylline Oral	Adenosine A _{2A} Receptor Antagonist	Parkinson's Disease	Filed in US Approved in JP March 2013	In-House	
		KW-6485 Topiramate Oral	Antiepileptic Drug	Pediatric Epilepsy	Filed in JP	Licensed from Janssen Research & Development, LLC	

Phase II, Phase III

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		KRN125 Pegfilgrastim Injection	Long-Acting Granulocyte Colony Stimulating Factor	Chemotherapy induced Febrile Neutropenia	Phase III in JP	Kirin- Amgen	
		©ARQ 197 Tivantinib Oral	c-Met Inhibitor	Lung Cancer (EGF-receptor mutated)	Phase II in JP	Licensed from ArQule	
				Gastric Cancer	Phase II in JP and KR		
		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Peripheral T/NK-cell Lymphoma	Phase II in JP	In-House	POTELLIGENT®
				Adult T-cell Leukemia/Lymphoma, Add-on Therapy (for Untreated Patients)	Phase II in JP		
				Peripheral T-cell Lymphoma	Phase II in EU		
				Adult T-cell Leukemia/Lymphoma	Phase II in US and EU		
	KRN1493 Cinacalcet Hydrochloride Oral	Calcium Receptor Agonist	Hypercalcemia with Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism	Phase III in JP	Licensed from NPS		
	©KW-2478 Injection	HSP90 inhibitor	Multiple Myeloma	Phase I / II in UK/US/PH	In-House		
	KRN321 Darbepoetin Alfa Injection	Long-Acting Erythropoiesis Stimulating Agent	Myelodysplastic Syndrome related Anemia	Phase II in JP and KR	Kirin- Amgen		
Nephrology		KRN321 Darbepoetin Alfa Injection	Long-Acting Erythropoiesis Stimulating Agent	Renal Anemia (on Dialysis)	Phase II in CN	Kirin- Amgen	
		©RTA 402 Bardoxolone Methyl Oral	Antioxidant Inflammation Modulator	CKD in patients with type 2 diabetes	Phase II in JP	Licensed from Reata	
Immunology /Allergy		©KHK4563 Benralizumab Injection	Anti-IL-5 Receptor Humanized Antibody	Asthma	Phase II in JP and KR	In-House	Being Developed by MedImmune as MEDI-563 Worldwide except in Japan and other Asian Countries POTELLIGENT®
		©ASKP 1240 Injection	Anti-CD40 Fully Human Antibody	Organ Transplant Rejection	Phase I in JP Phase II in US	In-House	Jointly Developed with Astellas KM mouse
		Z-206 Mesalazine Oral	pH Dependent Controlled Release Tablet	Crohn's Disease	Phase II in JP	Licensed from Zeria Pharma.	Jointly Developed with Zeria Pharma.
		©KHK4827 Injection	Anti-IL-17 Receptor Fully Human Antibody	Psoriasis	Phase III in JP	Kirin- Amgen	
Central Nervous System		©KHK6188 Oral	Cannabinoid CB2 Receptor Agonist	Neuropathic Pain	Phase II in JP	In-House	
Other		©KW-3357 Antithrombin Injection	Recombinant Human Antithrombin	Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency	Phase III in JP Phase I in EU	In-House	

Updated since Jan 24th, 2013 (Area, Stage, Filed, Approved, Launched etc.)

© New Molecular Entity

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		◎BIW-8962 Injection	Anti-GM2 Humanized Antibody	Cancer	Phase I / IIa in US	In-House	POTELLIGENT®
		◎KRN951 Tivozanib Oral	VEGF Receptor Inhibitor	Cancer	Phase I in JP	In-House	Filed in US by AVEO as AV-951
		◎CEP-37250/K HK2804 Injection	Anti-Tumor Specific Glycoprotein Humanized Antibody	Cancer	Phase I in US	Licensed from Cephalon	Jointly Developed with Cephalon POTELLIGENT®
		◎KHK2898 Injection	Anti-CD98 Fully Human Antibody	Cancer	Phase I in SG	In-House	POTELLIGENT® KM mouse
		◎ARQ 197 Tivantinib Oral	c-Met Inhibitor	Hepatocellular Cancer	Phase I in JP	Licensed from ArQule	
Nephrology		◎KHK7580 Oral	Calcium Receptor Agonist	Secondary Hyperparathyroidism	Phase I in JP	Licensed from Mitsubishi Tanabe	
Immunology /Allergy		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Asthma	Phase I in JP	In-House	POTELLIGENT®
		◎KHK4083 Injection	Immunomodulator	Autoimmune diseases	Phase I in CA	In-House	POTELLIGENT® KM mouse
		◎KHK4577 Oral	Anti-inflammatory Agent	Inflammatory disease	Phase I in JP	In-House	
Other		◎KRN23 Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemic Rickets/Osteomalacia (XLH)	Phase I / II in US and CA	In-House	KM mouse



Updated since Jan 24th, 2013 (Area, Stage, Filed, Approved, Launched etc.)

◎ New Molecular Entity

Updated since Jan 24th, 2013 (Area, Stage, Filed, Approved, Launched etc.)

Filed • Approved




As of April 17th 2013

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		Granisetron Patch	5HT3 Serotonin Receptor Antagonist	Chemotherapy induced Nausea and Vomiting	Approved in HK March 2013	Licensed from Sotasa Pharma (ProStrakan)	
Central Nervous System		◎KW-6002 Istradefylline Oral	Adenosine A2A Receptor Antagonist	Parkinson's Disease	Approved in JP March 2013	In-House	

Phase II, Phase III

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Immunology /Allergy		◎KHK4827 Injection	Anti-IL-17 Receptor Fully Human Antibody	Psoriasis	Phase III in JP	Kirin- Amgen	

Discontinuation

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Reason
Oncology		◎KW-2450 Oral	IGF-1 Receptor Signal Inhibitor	Cancer	Phase I / II in US	In-House	Revision for priority of product development portfolio in oncology area.
		◎KHK2866 Injection	Anti-HB-EGF Humanized Antibody	Cancer	Phase I in US	In-House	
		◎LY2523355 Litronesib Injection	M phase Kinesin Eg5 Inhibitor	Cancer	Phase I in JP	In-House	